The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
The U.S. Chamber of Commerce has sued to block the Federal Trade Commission’s (FTC's) recently finalized changes to the ...
Snyders Pharmacy, located in Oregon’s Ace Hardware, announced it has suspended operation of its drive-thru due to lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback